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Theneurodegenerativeaspectsofchronicprogressivemultiplesclerosis(MS)havereceivedincreasingattentionin
recent years, since anti-inflammatory and immunosuppressive treatment strategies have largely failed.
However, successful neuroprotection and/or neuroregeneration in MS have not been demonstrated yet.
Encouraged by the multifaceted neuroprotective effects of recombinant human erythropoietin (rhEPO) in
experimentalmodels, weperformedaninvestigator-driven, exploratoryopenlabelstudy (phase I/IIa) inpatients
with chronic progressive MS. Main study objectives were (i) evaluating safety of long-term high-dose intravenous
rhEPOtreatmentinMS,and(ii)collecting firstevidenceofpotentialefficacyonclinicaloutcomeparameters.
Eight MS patients, five randomly assigned to high-dose (48000 IU), three to low-dose (8000 IU) rhEPOtreat-
ment, and, as disease controls, two drug-nai«ve Parkinson patients (receiving 48 000 IU) were followed over up
to 48 weeks: A 6-week lead-in phase, a12-week treatment phase with weekly EPO, another12-week treatment
phase with bi-weekly EPO, and a 24-week post-treatment phase.Clinical and electrophysiological improvement
of motor function, reflected by a reduction in expanded disability status scale (EDSS), and of cognitive perfor-
mance was found upon high-dose EPO treatment in MS patients, persisting for three to six months after
cessation of EPO application. In contrast, low-dose EPO MS patients and drug-nai«ve Parkinson patients
did not improve in any of the parameters tested. There were no adverse events, no safety concerns and a
surprisingly low need of blood-lettings.
This first pilot study demonstrates the necessity and feasibility of controlled trials using high-dose rhEPO
in chronic progressive MS.
Keywords: recombinant human erythropoietin; EPO; primary and secondary progressive multiple sclerosis;
neuroprotection; neuroregeneration; neuropsychology; expanded disability status scale (EDSS); walking distance
Abbreviations: EDSS=expandedd isabil itystat usscale;EPO=e rythropoiet in;M CV=Meancorpuscularvol ume;
MCH=mean corpuscular haemoglobin; MEP=motor evoked potential; MRI=magnetic resonance imaging;
MS=multiple sclerosis
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Introduction
Understanding and treatment of the progressive phase of
multiple sclerosis (MS), which is characterized by the steady
accumulation of neurological disability, is far from being
satisfactory. Progression is most likely driven by the high
prevalence of neurodegenerative compared with inflamma-
tory pathological changes, explaining the limited long-term
efficacy of current anti-inflammatory and immunosuppres-
sive treatment strategies. It seems that once the cascade of
events leading to neuronal and axonal loss is established,
even an effective suppression of inflammation fails to
protect from clinical disease progression. The development
of add-on treatments targeting axonal repair and remyeli-
nation and/or the slowing of disease progression through
neuroprotection/neuroregeneration remains therefore the
most important challenge and goal in clinical management
of chronic progressive MS (Compston and Coles, 2002;
Bru ¨ck, 2005; Hauser and Oksenberg, 2006; Rovaris et al.,
2006).
Among potential candidate compounds for neuroprotec-
tion/neuroregeneration in progressive MS, erythropoietin
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 (EPO) appears to be a very promising agent. Originally
known as a haematopoietic growth factor, EPO has been
found in recent years to be part of a highly potent
endogenous neuroprotective system in the brain
(Ehrenreich et al., 2004a; Juul, 2004; Brines and Cerami,
2005; Jelkmann, 2005; Hasselblatt et al., 2006). As such, it
possesses a number of properties suitable to address several
of the pathophysiological mechanisms involved in progres-
sive MS. EPO acts in an anti-apoptotic and anti-oxidative
fashion, promotes neurite outgrowth and axonal repair,
neurogenesis and angiogenesis (Konishi et al., 1993;
Campana and Myers, 2001; Shingo et al., 2001; Siren
et al., 2001; Celik et al., 2002; Kertesz et al., 2004; Keswani
et al., 2004). These properties could be demonstrated, both
in vitro and in vivo, using a variety of different animal
models of diseases of the nervous system, including
hypoxia/ischaemia, neurotrauma, spinal cord injury, epi-
lepsy and Parkinson’s disease (Sakanaka et al., 1998;
Bernaudin et al., 1999; Brines et al., 2000; Genc et al.,
2001; Siren et al., 2006). Importantly, we could show that
EPO can prevent global brain atrophy in a mouse model
of chronic neurodegeneration (Siren et al., 2006). Several
groups, working on experimental autoimmune encephalitis
(EAE), an animal model of MS (Gold et al., 2006), could
demonstrate significant beneficial effects of EPO treatment
on clinical symptoms, proinflammatory cytokine expres-
sion, blood-brain-barrier integrity, electrophysiological and
histological findings (Agnello et al., 2002; Li et al., 2004;
Sattler et al., 2004; Diem et al., 2005; Zhang et al., 2005;
Savino et al., 2006). In vitro studies further support these
findings (Avasarala and Konduru, 2005; Genc et al., 2006).
Encouraging results on the neuroprotective/neurotrophic
efficacy of EPO in man have been obtained from our recent
treatment trials in stroke patients (Ehrenreich et al., 2002)
and in patients with chronic schizophrenia (Ehrenreich
et al., 2007). These trials underline that the translational
step from rodents to man for EPO is realistic.
The present investigation has been designed as an
exploratory open-label study (phase I/IIa) in preparation
for a double blind proof-of-concept (phase II) trial on EPO
treatment in chronic progressive MS. The main study
objectives were: (i) to evaluate safety of long-term high-
dose EPO treatment in chronic progressive MS, and (ii) to
collect first evidence of potential efficacy with respect to
a variety of clinical parameters, including walking distance,
Expanded Disability Status Scale (EDSS; Kurtzke, 1983),
fine motor function and cognition. A careful and
comprehensive individual follow-up of a small number of
patients during a 6-week lead-in phase, a 12–24 week
treatment phase and a 24-week post-treatment phase should
allow to consolidate plans for a consecutive phase II trial.
Further, this exploratory setting should help in determining
outcome parameters and estimating the number of patients
required for a future phase II trial. It should deliver
information about dosing of EPO, necessary duration of
treatment in order to see improvement, and effect of EPO
treatment-free periods on maintaining status. Finally, effects
found in chronic progressive MS should be compared
to effects observed in drug-naı ¨ve patients suffering from
another degenerative disease, Morbus Parkinson.
Materials and methods
Patients and procedures
Following announcement of the present exploratory study (‘EPO
MS study’) to the local ethical committee, a total of eight patients
suffering from chronic progressive MS (primary or secondary),
who had previously failed on disease-modifying drugs, and,
as disease control, two patients with Morbus Parkinson were
included (Table 1). Written informed consent was obtained after
comprehensive and repeated information of the respective patient
in the absence and in the presence of selected relatives or close
advisors (mostly physicians). Patients were fully aware that they
participated in a purely experimental study, set up to evaluate
safety and gain first impressions on efficacy of EPO in chronic
progressive MS.
The study was designed as an exploratory open-label study
employing two different doses of recombinant human (rh) EPO.
The high dose (48000IU of EPOa, ERYPO
R, Janssen-Cilag,
Germany) was selected as presumably effective dose, based on
our previous trials in stroke (Ehrenreich et al., 2002) and in
schizophrenia patients (Ehrenreich et al., 2007), whereas the low
dose (8000 IU of EPOa) lies in the middle to upper dose
range of anaemia treatment (e.g. Eschbach et al., 1987) and was
explored for the first time in a neurological indication. Of the
eight MS patients, five received high-dose rhEPO, whereas three
received low-dose rhEPO. Dosing was randomly assigned.
Patients were unaware of the dose being ‘high’ or ‘low’. The
two drug-naı ¨ve Parkinson patients received high-dose rhEPO
(48000 IU of EPOa).
An overview of the study design including tests and follow-up
parameters is presented in Fig. 1. After baseline examination and
confirmation of inclusion/exclusion criteria, patients entered a
lead-in phase of six weeks duration, where they were asked to
regularly score or test their performance in a number of items,
either specifically reflecting their individual handicaps or impor-
tant for general well-being and health. For that, every patient
received an individually tailored questionnaire, which should
provide insight into the longitudinally evaluated baseline per-
formance as well as, later, the treatment and post-treatment
follow-up period.
Following the lead-in period, the treatment period was initiated.
It started with a one-week inpatient setting, which allowed a
comprehensive examination of the patient including MRI of brain
and spinal cord, neurological, neuropsychological, electrophysio-
logical, urological, ophthalmological examination and routine
laboratory analyses (including EPO-antibody testing). Patients
were then started on high-dose prednisolone (1000mg/100ml over
30min intravenously) in order to create a comparable immuno-
suppression as a starting point of neuroprotective therapy
(Milligan et al., 1987). One day later, a second infusion of
prednisolone was given, followed by the first infusion of EPO
(48000 or 8000IU of EPOa, respectively, in 50ml of 0.9%
sodium chloride over 15min intravenously). The third treatment
day included prednisolone followed by EPO. Parkinson patients
did not receive prednisolone, but were otherwise treated
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 Table 1 Patient characteristics
T reatment group Patient
ID
Age (years) Sex Education
total
(years)
Premorbid
intelligence
quotient
a
Disease
duration
(years)
Disease
subtype
Optic nerve
involvement
b
Leading symptoms EDSS
upon
inclusion
Walking distance
upon inclusion
1 34 Female 19.5 118 9.2 PPMS None Tetraspastic (mainly legs/right side),
slight ataxia
5.5 88 m
2 42 Male 22 112 9.7 SPMS None Ataxia, dysarthria, urinary dysfunction,
mild cognitive deficits, fatigue,
inadequate affect
6.0 140 m (with crutch)
MS high-dose
(N=5)
3 53 Male 20.5 136 19.3 PPMS Bilateral Tetraspastic (mainly legs/left side),
urinary/bowel dysfunction, slight
fatigue
6.5 25 m (with walker)
4 44 Male 20.5 112 12.1 PPMS Bilateral Tetraspastic (mainly arms/right side),
ataxia, respiratory insufficiency
(muscle weakness)
5.5 110m
5 45 Female 20 143 14.8 SPMS None Tetraspastic, ataxia of upper limbs,
urinary/bowel dysfunction, fatigue,
dysthymia
6.0 77 m (intermittent
assistance)
43.6
(6.8)
m/f:
3/2
20.5
(0.9)
124.2
(14.4)
13.0
(4.1)
3 PPMS
2 SPMS
5.9
(0.4)
88.0
(42.7)
6 38 Male 20 130 9.5 PPMS Unilateral Ataxia, paraparesis, severe sensory
dysfunction, urinary dysfunction,
slight dysarthria
4.5 381 m
MS low-dose
(N=3)
7 42 Male 23 107 18.3 SPMS Bilateral Tetraspastic (mainly legs), urinary
dysfunction, cognitive deficits, INO,
dysarthria
6.5 54 m (with walker)
8 63 Female 23 136 10.4 SPMS None Paresis (mainly legs/right side), muscle
cramps, urinary dysfunction,
dysarthria
6.0 118 m (with cane)
47 .7
(13.4)
m/f:
2/1
22.0
(1.7)
124.3
(15.3)
12.7
(4.8)
1PPMS
2 SPMS
5.7
(1.0)
184.3
(173.3)
T reatment
group
Patient
ID
Age
(years)
Sex Education
total (years)
Premorbid
intelligence
quotient
a
Disease
duration
(years)
Disease
subtype
^ Leading symptoms UPDRS
upon
inclusion
^
Parkinson
high-dose
(N=2)
9 43 Male 24 145 1.8 Idiopathic ^ Tremor (mainly right side), rigidity,
bradykinesia, micrography, mild
cognitive deficits, dysarthria
30 ^
10 73 Female 18 118 0.7 Idiopathic ^ Tremor (mainly legs), bradykinesia,
impaired fine motor function,
fatigue, cognitive dysfunction
20 ^
Means (SD) presented for treatment groups ‘MS high-dose’ and ‘MS low-dose’. PPMS=primary progressive multiple sclerosis; SPMS=secondary progressive multiple sclerosis;
EDSS=expanded disability status scale;UPDRS=unified parkinson’s disease rating scale; INO=internuclear opthalmoplegia.
aPremorbid intelligence quotient based on results of the
Mehrfachwahl-Wortschatz-Intelligenztest (MWT-B).
bState of ophthalmological examination and VEPs (visual evoked potentials) upon study entry which remained unchanged during
follow-up.
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 identically. One day later, patients were discharged and asked to
return weekly to the clinic for application of the study drug,
documentation of clinical state, performance rating, monitor-
ing of adverse events and safety, including measurement of
blood pressure and routine laboratory workup. Blood-letting
(350–450ml) was performed if the haematocrit exceeded 50% in
male or 48% in female patients on two consecutive weeks. During
the 1-week inpatient phase, the 12–24 week outpatient treatment
phase, as well as the 24-week post-treatment phase, patients were
asked to continue regular (daily/weekly/monthly) self-rating using
their individually tailored questionnaire.
Neuropsychological baseline and follow-up testing of patients
included the Mehrfachwahl-Wortschatz-Intelligenztest (MWT-B;
Lehrl, 1999), for determination of the premorbid intelli-
gence quotient, four subtests (Information, Similarities, Picture
Completion, Block Design) of the revised German version of
the Wechsler Adult Intelligence Scale (HAWIE-R; Tewes, 1991),
the Repeatable Battery for the Assessment of Neuropsychological
Status (RBANS; Randolph, 1998), subtests Visual Scanning,
Working Memory and Alertness of the computer-assisted battery
for attention testing (TAP; Zimmermann and Fimm, 1995),
subtest Letter Number Sequencing of the Wechsler Memory
Scale – Revised (WMS-R; Wechsler, 1998), Wisconsin Card
Sorting Test – 64 Card Version (WCST-64; Kongs et al., 2000)
and the Trail Making Test (Reitan, 1958).
MRI of brain and spinal cord was conducted on a Siemens
1.5T scanner (scans before and after gadolinium; for cranial
imaging transverse, coronal and sagittal T1-weighted sequences,
T2-weighted TSE- and TIRM-sequences; for spinal imaging
sagittal and transverse T1-weighted TIRM- and TSE-sequences,
T2-weighted TSE-sequences; slice thickness: 6mm (19 slices,
cranial), 3mm (15 slices, cervical); 4mm (11 slices, thoracic);
semi-automated volumetrical analyses carried out, in a blinded
fashion, with Centricity Radiology RA 1000, General Electrics, in
T2-weighted images). Electrophysiology wherever technically
possible (motor evoked potentials: MEPs), maximum walking
distance, fine motor assessment using the 9-hole peg test (Cutter
et al., 1999; Rudick et al., 2001), as well as MacQuarrie Tapping
and Dotting tests (MacQuarrie, 1925, 1953) were performed.
Inclusion and exclusion criteria
An overview of all eight MS patients and the two Parkinson
patients is provided in Table 1. MS patients had to be in a chronic
progressive state (either primary or secondary) of their disease.
They had to be free of other severe psychiatric or neurological
disorders. A minimum of measurable walking distance was
required. Patients were not allowed to smoke or to take sex
steroid hormones to avoid a potential additional vascular risk on
top of their relative immobility. Two patients quit smoking several
weeks before the lead-in phase, another patient stopped taking
Fig. 1 Design of the EPO MS exploratory study. Low-dose EPO treatment was only performed until week12.
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 sex steroid medication (in accordance with her gynaecologist).
All medication had to be documented. Start of any MS-related
novel medication during the study was not allowed nor was any
kind of iron substitution. Previous medication in all MS patients
included corticosteroids, intrathecal prednisolone, beta interferon,
copaxone, mitoxantrone, cyclophosphamide, iv-immunoglobulins,
deoxyspergualin and riluzole. Treatment was terminated at least
half a year before EPO treatment due to lack of efficacy. All
patients had shown distinct progression of their disease in the
past year.
‘Consilium’: decision on study continuation
after 12 weeks
After 12 weeks of weekly EPO treatment, a so-called consilium
took place, integrating all test results and observations of all
participating parties, the patient, potential relatives or family
members, an independent MS specialist, members of the clinical
neuroscience team, a clinical neurophysiologist, a neuroradio-
logist, and a physiotherapist. Continuation of treatment was only
recommended if a patient had clearly improved performance in at
least three independent items, previously identified to be affected
in this particular individual, e.g. walking distance, cognition and
bladder function.
Statistical analysis
All numerical results are presented as meanSD. For analysis,
individual mean baseline performance in each of the items of
interest was set to 100% in order to reach comparable baseline
values among patients. Individual change during follow-up upon
treatment or during the treatment-free period was expressed in %
individual baseline. This way, patients could be compared and
intra-group comparisons investigating the course of various
variables in the high-dose EPO MS group, including all testing
time points from baseline on, could be performed using the
Friedman test of SPSS 14.0 for Windows. This special nonpara-
metric procedure for comparing repeated measures data with
small sample sizes can be used for metric as well as ordered
categorical data. Supplementary Tables 2 and 3 additionally
provide significance values based on analyses of raw scores.
Inter- and intra-group comparisons of MRI data were carried
out using the nonparametric Mann–Whitney-U-test (independent
and dependent). Statistical significance was set to 0.05 for all
analyses.
Results
Study participation
All 10 patients participated in the study until the consilium
took place after 12 weeks of weekly EPO treatment. At that
time point, only the five high-dose MS patients met criteria
for continuation, whereas all three low-dose EPO MS patients
as well as the two high-dose EPO Parkinson patients did not
show sufficient improvement that would have justified
continuation according to our consilium criteria for beneficial
treatment response. The five high-dose EPO MS patients
stayed on continuous treatment for another 12 weeks to
receive intravenous high-dose EPO now once every other
week. After this second treatment period, there was a 24-week
treatment-free follow-up period for all high-dose EPO MS
patients. One of these patients could be followed over another
EPO treatment cycle.
Safety
There were no adverse events reported or observed in any
of the patients at any time. One Parkinson patient
complained about being tired for approximately two to
three days after each EPO infusion. All other patients (high-
dose as well as low-dose EPO MS and Parkinson) reported
on feeling physically stronger, less tired, more optimistic,
more enduring. They did not report that their sleep was in
any way affected. Quality of life self-rating during that time
stayed stable (data not shown). No relapses were observed
in any of the MS patients during the study period. Mean
changes in blood cell counts and iron parameters during
and after EPO treatment are illustrated in Fig. 2. Original
data (meanSD) of high-dose and low-dose MS patients
and of Parkinson patients are presented in Supplementary
Table 1. The response of haemoglobin, haematocrit and
erythrocytes to EPO in MS patients was surprisingly low.
Of the high-dose EPO MS group, a total of only five blood-
lettings were necessary during the whole treatment phase
(three times in one patient and once in two patients; see
Supplementary Table 1). In the low-dose EPO group, no
blood-letting had to be performed. The two Parkinson
patients responded stronger to EPO and both required
blood-letting. Mean corpuscular volume (MCV) and mean
corpuscular haemoglobin (MCH) declined similarly
strongly in all high-dose patients. The iron parameters
showed the expected pattern, more pronounced upon high-
dose and less upon low-dose EPO treatment: distinct
decrease in serum ferritin levels, paralleled by increases in
serum transferrin and, particularly, in soluble transferrin
receptor (Fig. 2; Supplementary Table 1). Platelet counts
increased in all patients at approximately the same rate
but stayed essentially within the normal range.
Whereas there was no measurable change in CRP,
erythrocyte sedimentation rate tended to decrease in all
patients over time of EPO treatment. All patients were
EPO-antibody negative at baseline and none of the patients
had developed EPO antibodies by the end of the treatment
period. No appreciable change in blood pressure upon
EPO treatment was observed in any of the patients (data
not shown).
Motor function
All patients in the high-dose EPO MS group showed a
significant improvement in their maximum walking dis-
tance over time as compared to baseline, which became first
apparent after three weeks, gradually improved during the
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 Fig. 2 Changes in blood cell counts andiron parameters during and after EPO treatment.The mean of two baseline values of each patient
was set to100% for each of the laboratory parameters and used for calculating individual change over time. Mean change of all patients
within each group during follow-up upon treatment or during the treatment-free period is expressed in % baseline. Low-dose EPO MS
patients and Parkinson patients were only followed until week12.Filled circles: high-dose EPO MS patients (N=5); open circles: low-dose
EPO MS patients (N= 3); grey triangles: high-dose EPO Parkinson patients (N=2) .
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 treatment phase to reach a plateau at around eight weeks
and still persisted after cessation of EPO treatment (Fig. 3A
and B; Supplementary Table 2). The increase in maximum
walking distance in high-dose EPO MS patients resulted in
a reduction of the EDSS (Fig. 3C) and was paralleled
in patients, who could be followed electrophysiologically,
by a reduction in the central motor conduction time (left
Tibialis MEP; Fig. 3D, Supplementary Table 2). In contrast,
neither low-dose EPO MS patients nor Parkinson patients,
according to the Unified Parkinson’s Disease Rating Score
(Movement Disorder Society Task Force on Rating Scales
for Parkinson’s Disease, 2003; Fahn and Elton, 1987),
displayed any measurable beneficial effect on walking
distance/gait. Fig. 3B illustrates the course of the maximum
walking distance, both supervised and self-measurements,
over more than one year in one of the high-dose EPO MS
patients who underwent two EPO treatment periods. The
trend line from lead-in to the end of the observation period
clearly directs upwards, with no change after switch to
biweekly application. The EPO treatment break did not
provoke any loss of the gained function, underlining that
the effect of EPO is long lasting. Also, results of supervised
ratings and self-ratings were quite consistent.
Fine motor performance in MacQuarrie Tapping and
Dotting tests also showed improvement in high-dose EPO
MS patients only (Fig. 4A and B), whereas in the 9-hole peg
test, there was no significant beneficial effect of EPO
treatment in any group and no group difference (Fig. 4C;
Supplementary Table 2). Medianus MEP stayed stable over
time (Supplementary Table 2). Bladder function was
initially reported to be affected in three of the five high-
dose and all three low-dose EPO MS patients. Subjective
rating by the patients yielded distinct improvement
only upon high-dose EPO treatment (data not shown).
One MS patient with respiratory insufficiency due to
muscle weakness showed improvement in lung function
(vital capacity and forced vital capacity) upon high-dose
EPO treatment.
Cognitive functions
Premorbid intelligence as measured at baseline with the
MWT-B was almost identical in all MS patients (Table 1).
In contrast, estimation of the current intelligence using
HAWIE-R showed a higher variability (high-dose EPO MS:
132.815.4; low-dose EPO MS: 119.314.7). High-dose
EPO MS patients displayed a clear improvement in
cognitive tests related to executive functioning, i.e. Trail
Making – Part B, WMS-R Letter Number Sequencing,
Visual Scanning, RBANS Coding and Working Memory
and psychomotor speed (Trail Making – Part A), which was
absent both in low-dose MS and Parkinson patients (Fig. 5,
Supplementary Table 3). This improvement remained stable
even during the EPO treatment break. In contrast,
parameters of learning and memory (see Supplementary
Table 3 for the most relevant items) remained essentially
unchanged on a high performance level, consistent with
a ceiling effect.
Other outcome and follow-up parameters
Analysis of MRI data did not uncover changes upon EPO
treatment. Volumetrical analysis of total brain (excluding
cerebellum, brain stem and ventricles) as well as of
ventricles did not yield differences among high and low-
dose MS patients upon study entry (1195.865.6ml versus
1013.6189.7ml, P=0.4; and 48.317.6ml versus
46.412.8ml, P=0.857). Follow-up of the high-dose
patients after three months (3.61.1 months) showed no
change in total brain or ventricle volume compared to
baseline (baseline versus 3 months: 1195.865.6ml versus
1152.447.7ml, P=0.317; and 48.317.6ml versus
47.917.8ml, P=1.0). Serum levels of the glial damage
marker S100B did not reveal consistent changes in any of
the patients upon treatment (Supplementary Table 1).
Discussion
We present here the results of an open label study, designed
to explore safety and potential beneficial effects of long-
term EPO treatment in chronic progressive MS. In this
study, there were no adverse events, no safety concerns and
an astonishingly low need of blood-lettings. These findings
of the safety part of this pilot trial may be encouraging for
future studies but will certainly not make careful monitor-
ing of patients’ safety parameters dispensable. Using an
intra-individual follow-up design, we found significant
clinical and a tendency of electrophysiological improvement
of motor function in chronic progressive MS upon high-
dose EPO treatment, also reflected by a reduction in EDSS.
To our knowledge, improvement of this score has not yet
been observed in any chronic progressive MS trial, although
the non-blinded nature of our study limits the value of
these findings. Of course, in MS patients with a high
disability, EDSS only reflects walking ability and completely
disregards cognition or function of upper limbs. Therefore,
we included a comprehensive set of data measuring
cognitive functions. Indeed, cognitive performance was
also improved in high-dose EPO MS patients. Similarly, in
a recent double-blind proof-of-concept (phase II) study,
we had demonstrated cognitive improvement in chronic
schizophrenic patients upon high-dose EPO treatment over
12 weeks (Ehrenreich et al., 2007).
We do not think that these beneficial effects on motor
function and cognition are simply explained by improved
mood since an improvement in general well-being and
mood was observed in all patients, independent of the dose,
and became evident already after the first infusion of EPO.
In contrast to mood and general well-being, there was no
clear beneficial effect of low-dose EPO treatment in MS
patients on any of the other parameters tested and no
measurable effect of high-dose EPO treatment in the two
rhEPO in chronic progressive MS Brain (2007),130, 2577^2588 2583
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 Fig. 3 Changes in parameters of motor function upon EPO treatment. (A) The mean of all available baseline values of maximum walking
distance of each patient obtained during the whole lead-in period was set to100% and used for calculating individual change over time.
Mean change of all patients within each group during follow-up upon treatment or during the treatment-free period is expressed in
%b a s e l i n e .( B) Follow-up of maximum walking distance of one high-dose EPO MS patient over a total of 60 weeks, including two EPO
treatment periods, is presented as raw data for every test time point.The trend line illustrates the improvement over time. (C)F o r
presenting the course of EDSS scores during the study, mean individual baseline was set to 0 and subsequent values denote change of
EDSS score during follow-up of individual MS patients (left panel) or of mean EDSS score of the groups (right panel).For determining
individual EDSS change over time, the mean value of consecutive ratings over six week follow-up periods was used. (D) Intra-individual
course of central motor conduction time (Tibialis MEP, original data; MS high-dose patients N=4, due to methodological problems
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 drug-naı ¨ve Parkinson patients. These latter findings may
also exclude a pure placebo effect to explain the improve-
ment found in high-dose EPO MS patients.
The improvement was kept during EPO reduction and
even after complete cessation of EPO treatment over a
follow-up time of 24 weeks, pointing to a regenerative effect
mediated by EPO rather than a temporary and short-lived
action. These results may suggest an interval treatment
in future studies. It remains to be determined, however,
whether continuation of EPO treatment in MS patients
after a treatment-free interval will lead to further improve-
ment, or at least contribute to maintaining the improved
status and to slowing of progression. The observations
in one of our patients who could be followed over more
than one year and two EPO treatment cycles, would
support the assumption that the effect of EPO is a long-
lasting one.
Taken together, we were able to provide first evidence
that EPO may show an effect on the clinical course of
chronic progressive MS, acting via as yet undetermined
mechanisms that improve function, enhance regeneration
and/or slow deterioration. In line with our observations,
encouraging data had been obtained previously by different
groups showing beneficial effects of EPO in rodent studies
of EAE (Agnello et al., 2002; Li et al., 2004; Sattler et al.,
2004; Diem et al., 2005; Zhang et al., 2005; Savino et al.,
2006). In these animal models, various other agents have
also been found to improve outcome (Gold et al., 2006).
From a translational point of view, however, EPO is the
first compound that apparently leads to an improvement
in EDSS and a tendency of improvement in central
motor conduction time in a cohort of chronic progressive
MS patients.
Of note is the fact that all MS patients, high-dose as
well as low-dose EPO received the same three-day high-
dose corticosteroid infusion to create an immunologically
comparable starting point of long-term EPO therapy
(Milligan et al., 1987). Although no persisting beneficial
effects of steroid treatment per se would be expected (but
rather a potential rebound effect, i.e. a relapse of the disease
after discontinuation of therapy—Agnello et al., 2002), the
lasting clinical improvement exclusively in the high-dose
EPO MS group makes a steroid effect solely explaining
this improvement very unlikely. Interestingly, however,
we could demonstrate in a murine EAE model that a
combination of EPO and corticosteroids is superior to
each treatment on its own (Diem et al., 2005). Along the
same lines, Agnello and coworkers (2002) found EPO to
exert its effect by a mechanism different from steroids,
underlining the potential synergism of the two drugs.
Conversely, in a spinal cord injury model, the
Fig. 4 Changes in parameters of fine motor coordination upon
EPO treatment. (A) Change of performance in MacQuarrie
Tapping test, (B) MacQuarrie Dotting test and (C)9 - h o l ep e g
test, is expressed as % individual baseline.The mean of all available
baseline values of each patient was set to100% for each of these
parameters and used for calculating individual change over time.
Mean change of all patients within each group during follow-up
upon treatment or during the treatment-free period is expressed
in % baseline. Low-dose EPO MS patients and Parkinson patients
were only followed until week12.Filled circles: high-dose EPO MS
patients (N=5); open circles: low-dose EPO MS patients (N=3) ;
grey triangles: high-dose EPO Parkinson patients (N=2) .
Significance values refer to the high-dose EPO MS patients only
and denote changes of the respective parameter from baseline
to the end of each treatment period, including all testing time
points. Statistical analysis: Friedman test.
in one patient during baseline measurement). Low-dose EPO MS patients and Parkinson patients were only followed until week12.Filled
circles: high-dose EPO MS patients (N=5); open circles: low-dose EPO MS patients (N= 3); grey triangles: high-dose EPO Parkinson
patients (N=2). Significance values refer to the high-dose EPO MS patients only and denote changes of the respective parameter from
baseline to the end of each treatment period, including all testing time points. Statistical analysis: Friedman test.
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 neuroreparative effects of EPO were suspected to be
neutralized by glucocorticoids (Gorio et al., 2005). In this
regard, however, the obviously different pathologies under-
lying EAE versus injury, have to be considered.
Regarding the mechanism of action of EPO on motor
and cognitive performance in chronic progressive MS, the
observed gradual improvement, first visible after a latency
of several weeks, and, in particular, its stability over several
months of EPO reduction and EPO treatment-free interval,
may suggest a morphological rather than a purely func-
tional and transient effect. This assumption may be further
supported by the observed improvement of the central
motor conduction time. This improvement is particularly
striking and difficult to reconcile with the known spectrum
of EPO functions. Remyelination by EPO has not yet been
demonstrated, and effects of EPO on stimulating oligoden-
drocytes to remyelinate axons are presently under investiga-
tion in our laboratory. Interestingly, axon protecting
properties of EPO were already shown in the peripheral
nervous system (Keswani et al., 2004). Using conventional
MRI, including volumetrical analysis of the brain, however,
we could not yet find any clear-cut changes over time,
which is not too surprising in chronic progressive MS and
such a small group and short observation time.
Whereas the obvious failure of low-dose EPO to lead
to an appreciable improvement in MS patients might be
explained by an insufficient concentration of EPO achieved
in the central nervous system, it is unclear why the
Parkinson patients did not have any measurable benefit.
EPO penetrates through an intact blood-brain-barrier,
at least upon high-dose peripheral application (Brines
et al., 2000; Banks et al., 2004; Ehrenreich et al., 2004b;
Xenocostas et al., 2005), should therefore have reached the
brain also in the two Parkinson patients in amounts
sufficient to exert neurotrophic effects. In this disease,
however, symptoms become usually overt when 70% of
neurons in the substantia nigra are degenerated (Koller,
1992). Neurotrophic effects on the remaining neuronal
population may not lead to rapid clinical improvement or
require longer time periods of treatment and follow-up.
Fig. 5 Changes in cognitive function tests upon EPO treatment. (A) Decrease of reaction time inTrail Making ^ Part B. (B)I m p r o v e m e n t
of performance on WMS-R Letter Number Sequencing. (C and D) Reduction of reaction time inTAP subtests Visual Scanning ^ critical
trials and Working Memory in the high-dose EPO MS group (N=5). Low-dose EPO MS and Parkinson patients fail to show improvement.
The mean of two baseline values of each patient was set to100% for each of the cognitive parameters and used for calculating individual
change over time. Mean change of all patients within each group during follow-up upon treatment or during the treatment-free period is
expressed in % baseline.Low-dose EPO MS patients and Parkinson patients were only followed until week12.Filled circles: high-dose EPO
MS patients (N=5); open circles: low-dose EPO MS patients (N= 3); grey triangles: high-dose EPO Parkinson patients (N=2) .Si gnificance
values refer to the high-dose EPO MS patients only and denote changes of the respective parameter from baseline to the end of each
treatment period, including all testing time points. Statistical analysis: Friedman test.
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 The infrequent requirement of blood-lettings in MS
patients, consistent with a relative hyporesponsiveness
of the haematopoietic system to EPO (Kwack and
Balakrishnan, 2006), might be due to a systemic latent
inflammatory condition altering cytokine patterns that
modulate the bone marrow response to EPO. This
proposed latent inflammatory condition cannot be easily
diagnosed with routine laboratory parameters of inflamma-
tion. Here, the response of the haematopoietic system
to EPO might even serve in future studies of MS as
an indicator of occult inflammation, and thus require-
ment of additional immunosuppression. Moreover, the
hyporesponsiveness of the haematopoietic system, in
contrast to the nervous system, to EPO in MS supports
the notion that the observed therapeutic efficacy in MS is
not simply due to improved oxygen supply via increased
red blood cell mass.
EPO treatment leads to temporary shifts in iron stores as
delineated here by several determinants of iron metabolism.
Accelerated and intensified integration of iron into new red
blood cells and thereby withdrawal of iron from its stores,
leads to a picture similar to that of true iron deficiency.
This picture is corrected after termination of EPO
treatment without extra iron substitution. In the absence
of appreciable blood loss and upon normal nutrition, iron
deficiency will not occur. Binding more and more of the
freely available iron, on the other hand, might additionally
reduce inflammatory processes in MS and thereby con-
tribute to the beneficial effect of high-dose long-term EPO
treatment. In fact, iron chelators have been proposed for
treatment of MS (e.g. desferrioxamine; Lynch et al., 2000).
Interestingly, disturbed iron metabolism has been described
in MS patients (Sfagos et al., 2005) and iron-deficient mice
fail to develop autoimmune encephalomyelitis (Grant et al.,
2003; Weilbach et al., 2004).
Being aware that our explorative study included only a
small number of patients and no placebo group, we believe
that the encouraging results with high-dose EPO, con-
trasted by the lack of efficacy of low-dose EPO in MS
patients (with maintained blinding of patients to the EPO
dosage) and the non-responsiveness of high-dose EPO
treatment in Parkinson patients, deliver some pivotal
information for designing a phase II trial. Importantly,
long-term high-dose EPO treatment in MS was found to be
safe and well tolerated. Based on our results we propose a
double-blind, placebo-controlled proof-of-concept trial on
high-dose (48000 IU weekly) EPO treatment in chronic
progressive MS. As a primary outcome measure, the EDSS
should be applied, and supplemented by motor and
cognitive parameters as well as neurophysiology and MR
imaging as secondary outcome measures. The total duration
of this study should extend to three years with an
individual duration of two years (comprising at least two
EPO treatment cycles). We hope that the present work will
soon lead to an urgently warranted phase II trial.
Supplementary material
Supplementary material is available at Brain online.
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